Swiss Life Sciences Stock News

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Despite an already strong run, Bellevue Group AG ( VTX:BBN ) shares have been powering on, with a gain of 27% in the...

Key Insights Bucher Industries' significant retail investors ownership suggests that the key decisions are influenced...

Alcon (SWX:ALC) has quietly outperformed the broader healthcare space over the past month, with shares climbing about 4% even as the stock remains down sharply year to date. See our latest analysis for Alcon. That recent 30 day share price return of 3.84% looks more like a stabilisation than a full reversal. The year to date share price is still down 16.42%, and the one year total shareholder return is negative but modestly positive over three years. If Alcon’s move has you reassessing the...

Swissquote Group Holding SA's ( VTX:SQN ) price-to-earnings (or "P/E") ratio of 23.6x might make it look like a sell...

Clariant (SWX:CLN) has been grinding through a tricky stretch, with the share price down sharply this year even as revenue and net income inch higher. That disconnect is what matters for investors now. See our latest analysis for Clariant. With the share price now around CHF 7.12, a steep year to date share price loss contrasts with modest revenue and earnings growth. This suggests sentiment is still catching up to fundamentals and that momentum remains fragile rather than firmly...

Lonza Group AG ( VTX:LONN ) saw significant share price movement during recent months on the SWX, rising to highs of...

Idorsia Ltd ( VTX:IDIA ) shares have had a really impressive month, gaining 28% after a shaky period beforehand. The...

With a price-to-earnings (or "P/E") ratio of 37.5x Barry Callebaut AG ( VTX:BARN ) may be sending very bearish signals...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

With its stock down 7.7% over the past month, it is easy to disregard Adecco Group (VTX:ADEN). Given that stock prices...

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

UBS Group AG recently outlined further Credit Suisse integration steps, including multi-wave job cuts through 2026 and leadership changes in operations and technology, with Group Technology set to report to incoming Group Chief Operating Officer Beatriz Martin from January 2026. By consolidating technology under the Group COO and emphasizing artificial intelligence and IT migration, UBS is signaling a push to streamline operations while completing the complex Credit Suisse integration. We’ll...

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Huber+Suhner fair value estimate is CHF109 Current share price...

Key Insights The projected fair value for Amrize is CHF82.29 based on 2 Stage Free Cash Flow to Equity Current share...

Many investors define successful investing as beating the market average over the long term. But if you try your hand...

Jungfraubahn Holding's (VTX:JFN) stock is up by a considerable 29% over the past three months. Given that the market...

There wouldn't be many who think Compagnie Financière Tradition SA's ( VTX:CFT ) price-to-earnings (or "P/E") ratio of...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

Dätwyler Holding AG ( VTX:DAE ) shareholders should be happy to see the share price up 12% in the last month. But if...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...

If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...

Novartis (SWX:NOVN) has been grinding higher, with shares up around 7 % over the past month and nearly 30 % over the past year, as investors lean into its steady earnings and pipeline story. See our latest analysis for Novartis. That move has been underpinned by solid execution rather than hype, with the roughly 30 % one year total shareholder return riding a clear uptrend in the share price as investors warm to its growth and defensiveness. If Novartis has you rethinking your healthcare...